Send us Fan Mail

A marketplace can tell you more about the economy than a headline number, especially when thousands of everyday jobs are priced in real time. We sit down with Tim Fung to break down Airtasker’s Q3 performance and what’s really driving momentum in Australia: rising job volumes, strong completion rates, and an uplift in average task prices that reflects both demand and the cost-of-living squeeze pushing more people to earn on-platform. We also talk candidly about what’s next as consumer sentiment darkens and interest rate settings start to bite.

From there, we zoom out to the brand battle. Airtasker’s focus is simple: when a roof leaks, a tap drips, or IKEA furniture needs assembling, we want Airtasker to be the first name people think of. We unpack the strategic media partnership with Nine Entertainment and how it complements other channels to lift unprompted brand awareness, while also using the balance sheet in a disciplined way through delayed settlement structures.

Internationally, the story splits in two. The UK approaches a scale point where the marketplace can become cash generative quickly with low fixed costs, while the US remains in build mode, investing to strengthen network effects. We also cover the newer membership product, designed to lift frequency and create sticky recurring revenue through an annual fee and added credits. If you care about the gig economy, marketplace growth, ASX tech, and how pricing power shows up in the real world, this one is packed with signal. Subscribe, share it with a mate, and leave a review so more people can find the show.

Send us Fan Mail

“Recycled” sounds simple until you ask one awkward question: what exactly was recycled to make this product? We’re joined by Marie De Perthuis, CEO of MyEco Group Limited, to talk about how sustainable packaging earns trust when greenwashing is everywhere and shoppers are time-poor at the shelf.

We get a clear view of MyEco Group’s model: a Melbourne-based brand with manufacturing and R&D capability that supports traceability from resin to finished goods. Marie explains why third-party certification (including GRS for post-consumer recycled materials) is more than a logo. It’s how retailers and consumers separate credible recycled content from vague claims, and how a category lifts its standards without asking shoppers to do forensic research.

We also dive into growth drivers across two big channels. On the retail side, the new GRS certified post-consumer recycled bin liner range launching at Woolworths marks a major step beyond compostables and into a much larger market that directly competes with virgin plastic. On the council side, we unpack FOGO rollouts, tender wins, and why organics diversion, contamination reduction and landfill pressure are pushing councils to act sooner rather than later.

If you care about sustainable packaging in Australia, compostable caddy liners, soft plastic recycling, or what “real” recycled content looks like at scale, this conversation delivers practical detail and a straightforward checklist for cutting through the noise. Subscribe, share the episode with a mate, and leave a review, then tell us: what do you look for before you trust a sustainability claim?

Send us Fan Mail

A small ASX biotech can feel impossible to value until the data starts landing, and that’s exactly where Syntara is headed. We’re joined by CEO Gary Phillips to map out a tight run of clinical catalysts and the thinking behind a pipeline built around extracellular matrix dysfunction and amine oxidase chemistry, backed by specialist institutional investors and real in-house drug discovery.

We dig into Amsulostat, the lead program in myelofibrosis, and what positive FDA feedback actually means in practice: a clearer regulatory development pathway, a Phase 2B add-on design against placebo alongside JAK inhibitor standard of care, and stronger footing for potential partnering conversations in hematology and oncology. Gary also explains why safety and symptom score improvements matter so much at this stage, especially in diseases where current options can be hard to tolerate.

From there we switch gears into two more high-interest areas. In myelodysplastic syndrome (MDS), we cover the unmet need, the significance of grant-backed trials in Germany and Australia, and why indication expansion can materially lift an asset’s commercial upside. We also explore SNT 4728 in isolated REM sleep behavior disorder (IRBD), a sleep condition that can precede Parkinson’s disease, and how a placebo-controlled study funded by Parkinson’s UK uses brain imaging to look for reduced inflammation. Finally, we talk skin scarring, including hypertrophic and keloid scars, why function and mental health outcomes matter, and what a once-daily topical approach could mean if results stack up.

If you follow ASX biotech, clinical trials, FDA pathways, or early signals in Parkinson’s research, this chat is built for your watchlist. Subscribe, share the episode with a mate who tracks biotech's, and leave us a review so more people can find the show.